Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- didanosine
- Myhibbin (mycophenolate mofetil)
Interactions between your drugs
didanosine mycophenolate mofetil
Applies to: didanosine, Myhibbin (mycophenolate mofetil)
ADJUST DOSING INTERVAL: Coadministration with antacids may decrease the oral bioavailability of mycophenolic acid. The exact mechanism of interaction is unknown but may involve chelation with polyvalent ions in antacids or enhanced drug solubility induced by an increase in gastric pH, or both. The interaction has been reported with magnesium/aluminum-containing antacids.
MANAGEMENT: Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.g., didanosine buffered tablets or pediatric oral solution) should separate the administration times of the medications by at least two hours.
References (4)
- (2001) "Product Information. CellCept (mycophenolate mofetil)." Roche Laboratories
- Bullingham R, Shah J, Goldblum R, Schiff M (1996) "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol, 41, p. 513-6
- Lipsky JJ (1996) "Mycophenolate mofetil." Lancet, 348, p. 1357-9
- (2004) "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals
Drug and food interactions
didanosine food
Applies to: didanosine
ADJUST DOSING INTERVAL: Didanosine bioavailability is decreased when administered with food. Loss of efficacy may result.
MANAGEMENT: Didanosine should be administered in the fasting state, at least 30 minutes before or more than 2 hours after eating.
References (1)
- (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Complera
Complera (emtricitabine, rilpivirine, and tenofovir) is used to treat HIV infection. Includes ...
Stribild
Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is used to treat HIV-1 infection ...
Epzicom
Epzicom is used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). Learn ...
Lamivudine
Lamivudine is used for hepatitis b, HIV Infection, nonoccupational exposure, occupational exposure
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.